Vicarious Surgical (RBOT) Expected to Announce Quarterly Earnings on Monday

Vicarious Surgical (NYSE:RBOT) is anticipated to post its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect Vicarious Surgical to post earnings of ($1.37) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 16, 2026 at 4:00 PM ET.

Vicarious Surgical Stock Down 43.5%

RBOT stock opened at $0.52 on Monday. The company has a 50-day simple moving average of $2.14 and a 200 day simple moving average of $3.81. The company has a market capitalization of $3.40 million, a P/E ratio of -0.06 and a beta of 1.53. Vicarious Surgical has a fifty-two week low of $0.27 and a fifty-two week high of $13.75.

Hedge Funds Weigh In On Vicarious Surgical

Large investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in shares of Vicarious Surgical in the 4th quarter worth approximately $27,000. Geode Capital Management LLC boosted its holdings in Vicarious Surgical by 26.0% during the fourth quarter. Geode Capital Management LLC now owns 40,494 shares of the company’s stock worth $88,000 after buying an additional 8,344 shares in the last quarter. Jane Street Group LLC bought a new stake in Vicarious Surgical during the fourth quarter worth approximately $98,000. Dimensional Fund Advisors LP grew its position in Vicarious Surgical by 22.1% in the third quarter. Dimensional Fund Advisors LP now owns 19,975 shares of the company’s stock worth $110,000 after buying an additional 3,615 shares during the last quarter. Finally, Connective Capital Management LLC acquired a new position in Vicarious Surgical in the third quarter worth approximately $169,000. Institutional investors own 47.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on RBOT. Wall Street Zen lowered shares of Vicarious Surgical from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research reissued a “neutral” rating on shares of Vicarious Surgical in a report on Friday, December 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Vicarious Surgical in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $7.00.

Vicarious Surgical Company Profile

Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.

The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.